Research News for 2009
-
American Society Clinical Oncology Now Recommends Evista or Tamoxifen to Reduce Risk in High-Risk Women
New guidelines from the American Society of Clinical Oncology (ASCO) now recommend both tamoxifen and Evista (chemical name: raloxifene) to reduce breast cancer risk in post-menopausal women at high risk.
-
Certain Risk Factors Affect Different Types of Breast Cancer in Different Ways
A new study found that certain risk factors for breast cancer affect the risk of specific types of breast cancer in different ways.
-
Adding Taxotere to Standard Chemo Doesn’t Seem to Help Treat Early-Stage Breast Cancer
Taxotere doesn't seem to offer any benefits in treating early-stage breast cancer and also causes more serious side effects.
-
Older Women Do Better on Conventional Chemo Compared to Xeloda
Research shows that women older than 65 do better on standard intravenous chemotherapy after surgery to remove early-stage breast cancer than Xeloda (chemical name: capecitabine), an oral chemotherapy.
-
Molecular Test During Surgery May Help Find Cancer in Lymph Nodes
A test that quickly detects cancer cells in a lymph node during surgery to remove breast cancer is accurate enough to help doctors decide if lymph nodes need to be removed during the surgery.
-
Water Content of Breasts May Help Determine Risk
An early study suggests that figuring out the water content of a young woman's breast tissue may help predict her risk of breast cancer later in life.
-
HER2 and Topo II Status Affects Response to Anthracycline Chemo
A new study suggests that anthracycline-based chemotherapy regimens should be used to treat only HER2-positive breast cancers.
-
Tykerb May Help Treat HER2-Positive Inflammatory Breast Cancer
Tykerb (chemical name: lapatanib) may be effective against HER2-positive inflammatory breast cancer after other treatments don't work any more.
-
Smoking and Secondhand Smoke Raise Risk
A new meta-analysis confirms a link between both smoking and exposure to secondhand smoke and an increase in breast cancer risk.
-
New Imaging Device Shows Promise for Assessing Margins at Time of Surgery
An experimental imaging device may some day offer almost instant analysis of tumor margins during lumpectomy.
